Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 119 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading ESMO Welcomes European Parliament Resolution Marking World Cancer Day MOST POPULAR A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading February 12, 2026 Cancer in My Community: Working to Expand Access to Clinical Trials... September 22, 2022 Changes in Metabolism Help Melanomas Spread January 21, 2020 Load more HOT NEWS What Are Social Determinants of Health and How Do They Affect... Longer Duration of Treatment with ICIs Associated with a Higher Rate... FDA Approves Second CAR T-Cell Therapy for Lymphoma Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy
